Divi's Laboratories Ltd. (DIVISLAB) fundamentals
Divi's Laboratories Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as DIVISLAB (ISIN INE361B01024). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Divi's Laboratories Ltd. does
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
Valuation and market data
| Last close | ₹9050.00 |
|---|---|
| Market capitalisation | ₹2.40 lakh crore |
| Enterprise value | ₹2.41 lakh crore |
| P/E (TTM) | 93.54 |
| Price to book | 14.33 |
| Price to sales (TTM) | 12.47 |
| Book value per share | ₹631.48 |
| Dividend yield | 33.15% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Mar 12 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹10,894 crore | ₹3,436 crore | ₹2,607 crore | 98.19 |
| Mar 2025 | ₹9,550 crore | ₹2,929 crore | ₹2,209 crore | 83.20 |
| Mar 2024 | ₹8,002 crore | ₹2,132 crore | ₹1,576 crore | 59.37 |
| Mar 2023 | ₹7,974 crore | ₹2,354 crore | ₹1,808 crore | 68.11 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 51.9% |
|---|---|
| Foreign institutions (FII) | 20.4% |
| Mutual funds | 14.7% |
| Other domestic institutions | 4.5% |
| Retail and others | 8.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.